Sat, Jan 31, 2015, 3:43 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

SIGA Technologies, Inc. Message Board

minnesotafarmcountry 21918 posts  |  Last Activity: 11 hours ago Member since: Apr 24, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • minnesotafarmcountry minnesotafarmcountry 11 hours ago Flag

    Weird?

  • Reply to

    STRENGTH

    by minnesotafarmcountry 12 hours ago
    minnesotafarmcountry minnesotafarmcountry 11 hours ago Flag

    Yeah, the darned website has been down for a few days ... can't figure out why.

    Fairly recent IPO ... based on valuation, I started buying it.

    Summary
    •FOMX, a specialty pharmaceutical company seeking to develop treatments for skin conditions, plans to raise $65.0 million in its upcoming IPO.
    •The Rehovot, Israel-based firm posted extremely promising results of FOMX's Phase II trial of product FMX101.
    •The U.S. market for branded prescription acne drugs alone for the twelve months ended March 31, 2014 has been estimated at $2.6 billion.
    •We are optimistic that FOMX might capture a strong market share and have a successful IPO.

    Foamix Pharmaceuticals Ltd. (Pending:FOMX), a specialty pharmaceutical company seeking to develop treatments for skin conditions, plans to raise $65.0 million in its upcoming IPO.

    The Rehovot, Israel-based firm will offer 5.9 million shares at an expected price range of $10-$12 per share. If the IPO hits the midpoint of that range at $11 per share, FOMX will command a market value of $261 million

    FOMX filed on August 13, 2014

    Lead Underwriters: Barclays Capital Inc; Cowen and Company, LLC

    Underwriters: Maxim Group, LLC; Oppenheimer and Co., Inc

    Summary: Strong, Diverse Pipeline For Skin Condition Treatments

    FOMX is a clinical-stage pharmaceutical firm engaged in the development and commercialization of treatments for skin conditions. The firm's two lead product candidates, FMX101 and FMX102, are both topical foam formulations of minocycline, a antibiotic commonly used in the treatment of acne and other skin infections as well as pneumonia and other infections. FMX101 is currently in development to treat moderate-to-severe acne, while FMX102 is being developed for the treatment of impetigo, a highly contagious skin infection that typically affects children and infants.

    FOMX has completed Phase II clinical trials of each of these product candidates; based on the results of the trial of FMX101, the firm believes that its topical foam could become the standard of care for moderate-to-severe acne, as FMX101 performed more quickly and effectively than orally ingested minocycline, which is the current standard of care. FMX101 also lacks many of the systemic side effects associated with orally ingested minocycline, which include nausea, headaches, and severe itchiness, as well as several uncommon but far more severe side effects. FMX102's Phase II trial also produced promising results, though it would be one of many options for impetigo treatment if it received FDA approval. FOMX plans to initiate pivotal Phase III studies of both FMX101 and FMX102 in 2015.

    FOMX has already generated some revenues through its proprietary foam-based platforms, which it has used to develop FMX101 and FMX102. The firm has entered into licensing and development agreements with firms such as Bayer AG, Merz Pharmaceutical, and Actavis plc (NYSE:ACT) related to its technologies.

    See FOMX's website for the full pipeline and current products.

    Valuation

    FOMX offers the following figures in its F-1 balance sheet for the six months ended June 30, 2014:

    Revenue: $2,006,000.00

    Net Loss: ($3,473,000.00)

    Total Assets: $11,378,000.00

    Total Liabilities: $4,135,000.00

    Stockholders' Equity: ($6,195,000.00)

    Hot Competition From Existing Acne Treatments

    Though FMX101 may represent a significant advance in the treatment of acne, the drug will still face significant competition from other acne treatments in the event that it receives FDA approval. Some of these drugs are marketed by companies with access to substantially greater financial and marketing resources than FOMX. Major potential competitors include Valeant Pharmaceuticals (NYSE:VRX), Actavis plc , and Galderma.

    Management: Industry, Academic Credentials

    Dov Tamarkin , Ph.D., has served as FOMX's CEO since January 2003. He previously served as Vice President of R&D at Portman Pharmaceuticals, Inc. and as Senior R&D Manager at Teva Pharmaceutical Industries Ltd. Dr. Tamarkin received a Ph.D. in chemistry from The Hebrew University of Jerusalem.

    Conclusion: Investors Should Seriously Consider FOMX

    We are optimistic on this IPO.

    Despite a plethora of brands, acne treatments have generated huge revenues worldwide; the U.S. market for branded prescription acne drugs for the twelve months ended March 31, 2014 has been estimated at $2.6 billion.

    Given the extremely promising results of FOMX's Phase II trial of FMX101, we believe that the firm has every opportunity to capture a significant share of this market.

    The firm's proprietary foam delivery technologies are also intriguing, as they have already begun to generate revenue for FOMX and may allow the firm to develop many more topical treatments in the future.

    Between these factors and FOMX's history of stable management, this IPO merits serious investor consideration.

  • Reply to

    Hellooooo ...

    by minnesotafarmcountry Jan 26, 2015 2:05 PM
    minnesotafarmcountry minnesotafarmcountry 11 hours ago Flag

    Anyone impressed today? Good volume and we stayed green ALL day!

  • minnesotafarmcountry by minnesotafarmcountry 11 hours ago Flag

    Keep your eye on OSIR ... buying opps coming! But, it's so thinly traded, you will need your buys set, imo.

    I'm going to put one in for $15.50-ish! Market is getting uglier by the day!!

  • Reply to

    STRENGTH

    by minnesotafarmcountry 12 hours ago
    minnesotafarmcountry minnesotafarmcountry 12 hours ago Flag

    Kitty,
    Take a look at FOMX and see what you think ... it, too, has been holding real well all week! Appreciate your opinion!!

  • minnesotafarmcountry by minnesotafarmcountry 12 hours ago Flag

    I can't recall ever seeing a stock as resilient as CEMP!!!

  • minnesotafarmcountry minnesotafarmcountry 12 hours ago Flag

    Frankly, we've had a lot of good pr(s) fairly recently and the market seems to yawn. We continue to consolidate at these levels. Not entirely a bad thing. I think the only thing that is going to catapult this higher will be bona fide blow out earnings and out of this world guidance! Can't wait!!

  • minnesotafarmcountry minnesotafarmcountry 12 hours ago Flag

    FOMX, CERS

  • minnesotafarmcountry minnesotafarmcountry 12 hours ago Flag

    Institutions are gobbling us up!!! And, they are NOT selling any time soon!!

  • minnesotafarmcountry minnesotafarmcountry 13 hours ago Flag

    Well, there was a little "gamesmanship" in play there ... heading for new HOD and "someone" pulled the rug out!!

  • minnesotafarmcountry minnesotafarmcountry 14 hours ago Flag

    Stop with the UGLY pumps, will you? We're smarter than that!

  • Reply to

    11 million shares. We're good.

    by easttexasdoug 18 hours ago
    minnesotafarmcountry minnesotafarmcountry 14 hours ago Flag

    Well, YHOO page has 107 O/S now, plus the roughly 12M new shares = 119? Quite a difference between 129 and 119 - nearly 10%

  • minnesotafarmcountry by minnesotafarmcountry 15 hours ago Flag

    Remember when we kept knocking on the $27 door and "some" said we couldn't break the wall? Well ... wash, rinse, repeat!!

  • Reply to

    11 million shares. We're good.

    by easttexasdoug 18 hours ago
    minnesotafarmcountry minnesotafarmcountry 15 hours ago Flag

    Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Griffin Securities, Inc. is acting as a co-manager for the offering.

    I know market conditions have a lot to do with where/when/how you can place an offering. But with Griffin's very optimistic price target, I wonder why they had to place it at $3.75? Guess they got their friends in cheap!!!

  • Reply to

    QUESTION

    by itsalongroad75 16 hours ago
    minnesotafarmcountry minnesotafarmcountry 15 hours ago Flag

    Danny,
    Where did you hear 4x? Only other stock I own that did a secondary that was 4x subscribed was CEMP and, yes, it did touch the offering price, but hasn't looked back since!

  • minnesotafarmcountry by minnesotafarmcountry 16 hours ago Flag

    FOMX? Just wondering since it is in the antibiotic space. Not new antibiotics, but new form of delivery. Very low float ... owned big by Baker Bros., and holding up very nicely in the ugly market! Been in since the $7's.

  • Reply to

    QUESTION

    by itsalongroad75 16 hours ago
    minnesotafarmcountry minnesotafarmcountry 16 hours ago Flag

    I think that the book running companies offer the shares to their customers.

  • Reply to

    Do the math

    by ozark580 Jan 29, 2015 12:37 PM
    minnesotafarmcountry minnesotafarmcountry 16 hours ago Flag

    "Mac"
    Downside is limited, but COULD happen. Set a buy lower ... leave it. This is one perplexing stock to own. It requires the patience of Job because it may not move for a long time, but things are definitely looking up behind the scenes!!!

  • Reply to

    11 million shares. We're good.

    by easttexasdoug 18 hours ago
    minnesotafarmcountry minnesotafarmcountry 16 hours ago Flag

    And, Bernard ... just to get you clearly on record here and now. You sold and have no position ... waiting to enter in the low $3's? Is that correct. Because I wouldn't want you coming on here after another contract announcement telling us you actually went REAL long at $4. Call me a skeptic?

  • Reply to

    11 million shares. We're good.

    by easttexasdoug 18 hours ago
    minnesotafarmcountry minnesotafarmcountry 16 hours ago Flag

    Funny ... you didn't express those concerns before? Yeah ... I sold ALL mine up hear $4.90, too!

SIGA
1.41+0.01(+0.71%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.